Skip to search formSkip to main contentSkip to account menu

fotemustine

Known as: 1-[N-(2-chloroethyl)-N-nitrosoureido]ethylphosphonic acid diethyl ester, diethyl[1-[3-(2-chloroethyl)-3-nitrosoureido]ethyl]phosphonate, diethyl-1-(3-(2-chloroethyl)-3-nitrosoureido)ethylphosphonate 
A chloroethylating nitrosourea with antineoplastic activity. Fotemustine alkylates guanine by forming chloroethyl adducts at the 6 position of… 
National Institutes of Health

Related topics

Related topics

6 relations

Broader (3)

Antineoplastic AgentsNitrosourea CompoundsOrganophosphorus Compounds

Narrower (2)

MuphoranS 10036
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Treatment patterns of advanced malignant melanoma (stage III-IV) - A review of current standards in Europe.
Review
2013
Review
2013
Advances in therapy for melanoma brain metastases.
2004
2004
Positive phase II study in the treatment of advanced malignant melanoma with fotemustine
SummaryTo date, dacarbazine (DTIC) has been the most effective drug in the treatment of advanced metastatic melanoma, achieving… 
1999
1999
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.
BACKGROUND The DNA repair protein O6-alkylguanine-DNA alkyl transferase (AT) mediates resistance to chloroethylnitrosoureas… 
Highly Cited
1999
Highly Cited
1999
Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6‐methylguanine‐DNA methyltransferase and N‐methylpurine‐DNA glycosylase in melanoma cells with acquired drug resistance
Malignant melanoma is well known for its primary unresponsiveness to chemotherapy. The mechanisms conferring this intrinsic… 
1998
1998
Modulation of O6-alkylating agent induced clastogenicity by enhanced DNA repair capacity of bone marrow cells.
Highly Cited
1997
Highly Cited
1997
Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Melanoma cells often display a multidrug-resistant phenotype, but the mechanisms involved are largely unknown. In order to… 
Highly Cited
1995
Highly Cited
1995
Palliative therapy of melanoma patients with fotemustine. Inverse relationship between tumour load and treatment effectiveness. A multicentre phase II trial of the EORTC‐Melanoma Cooperative Group…
Fotemustine (FM) is a new chloronitrosurea (CNU), chemically characterized by the graft of an aminophosphonic acid on the CNU… 
Review
1994
Review
1994
Fotemustine in the treatment of brain primary tumors and metastases.
Fotemustine is a new chloroethylnitrosourea characterized by the grafting of a phosphonoalanine group onto a nitrosourea radical… 
1991
1991
Liver targeting of autologous erythrocytes loaded with doxorubicin.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)